$2.42
0.67%
Downside
Day's Volatility :1.89%
Upside
1.22%
32.23%
Downside
52 Weeks Volatility :47.77%
Upside
22.93%
Period | Cronos Group Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -6.56% | 6.5% | 0.0% |
6 Months | 23.47% | 7.1% | 0.0% |
1 Year | 33.7% | 9.8% | 0.0% |
3 Years | -66.8% | 14.2% | -20.2% |
Market Capitalization | 911.6M |
Book Value | $2.82 |
Earnings Per Share (EPS) | -0.14 |
Wall Street Target Price | 2.62 |
Profit Margin | -61.31% |
Operating Margin TTM | -54.93% |
Return On Assets TTM | -4.03% |
Return On Equity TTM | -4.99% |
Revenue TTM | 93.0M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | 29.7% |
Gross Profit TTM | 12.0M |
EBITDA | -66.2M |
Diluted Eps TTM | -0.14 |
Quarterly Earnings Growth YOY | 0.14 |
EPS Estimate Current Year | -0.08 |
EPS Estimate Next Year | -0.01 |
EPS Estimate Current Quarter | -0.01 |
EPS Estimate Next Quarter | -0.01 |
What analysts predicted
Upside of 8.26%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 11.5M | ↑ 255.17% |
Net Income | -13.9M | ↓ 803.1% |
Net Profit Margin | -120.8% | ↓ 181.82% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 23.8M | ↑ 106.0% |
Net Income | 2.5B | ↓ 17729.39% |
Net Profit Margin | 10.3K% | ↑ 10459.23% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 46.7M | ↑ 96.71% |
Net Income | -74.6M | ↓ 103.04% |
Net Profit Margin | -159.72% | ↓ 10498.15% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 74.4M | ↑ 59.32% |
Net Income | -396.7M | ↑ 431.63% |
Net Profit Margin | -532.95% | ↓ 373.23% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 91.9M | ↑ 23.47% |
Net Income | -168.7M | ↓ 57.47% |
Net Profit Margin | -183.6% | ↑ 349.35% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 88.8M | ↓ 3.33% |
Net Income | -75.2M | ↓ 55.43% |
Net Profit Margin | -84.64% | ↑ 98.96% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 22.9M | ↑ 9.39% |
Net Income | -78.9M | ↑ 113.79% |
Net Profit Margin | -344.55% | ↓ 168.26% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 20.1M | ↓ 11.98% |
Net Income | -19.3M | ↓ 75.58% |
Net Profit Margin | -95.6% | ↑ 248.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 19.0M | ↓ 5.57% |
Net Income | -8.4M | ↓ 56.59% |
Net Profit Margin | -43.95% | ↑ 51.65% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 33.9M | ↑ 78.29% |
Net Income | -1.6M | ↓ 80.33% |
Net Profit Margin | -4.85% | ↑ 39.1% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 24.6M | ↓ 27.53% |
Net Income | -46.0M | ↑ 2700.63% |
Net Profit Margin | -187.35% | ↓ 182.5% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 25.2M | ↑ 2.44% |
Net Income | -2.2M | ↓ 95.15% |
Net Profit Margin | -8.86% | ↑ 178.49% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 191.7M | ↑ 138.62% |
Total Liabilities | 36.3M | ↑ 211.59% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 2.1B | ↑ 990.4% |
Total Liabilities | 341.4M | ↑ 839.82% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.9B | ↓ 7.88% |
Total Liabilities | 217.5M | ↓ 36.29% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↓ 27.42% |
Total Liabilities | 63.5M | ↓ 70.82% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↓ 13.22% |
Total Liabilities | 72.0M | ↑ 13.52% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↓ 6.49% |
Total Liabilities | 43.7M | ↓ 39.29% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 1.98% |
Total Liabilities | 72.0M | ↑ 55.85% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 4.41% |
Total Liabilities | 33.2M | ↓ 53.95% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↑ 0.76% |
Total Liabilities | 31.7M | ↓ 4.52% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.2B | ↓ 1.56% |
Total Liabilities | 33.3M | ↑ 5.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 1.38% |
Total Liabilities | 43.7M | ↑ 31.15% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 1.1B | ↓ 2.37% |
Total Liabilities | 35.7M | ↓ 18.33% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -7.2M | ↑ 62.07% |
Investing Cash Flow | -93.9M | ↑ 214.11% |
Financing Cash Flow | 113.5M | ↑ 185.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -130.0M | ↑ 1718.19% |
Investing Cash Flow | -603.5M | ↑ 542.69% |
Financing Cash Flow | 1.9B | ↑ 1535.55% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -142.5M | ↑ 9.58% |
Investing Cash Flow | 20.2M | ↓ 103.34% |
Financing Cash Flow | -5.5M | ↓ 100.29% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -153.6M | ↑ 7.83% |
Investing Cash Flow | -28.9M | ↓ 243.41% |
Financing Cash Flow | -13.4M | ↑ 145.97% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -88.9M | ↓ 42.1% |
Investing Cash Flow | -1.8M | ↓ 93.63% |
Financing Cash Flow | -2.9M | ↓ 78.45% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -24.4M | ↑ 82.08% |
Investing Cash Flow | 158.5M | ↓ 232.07% |
Financing Cash Flow | -620.0K | ↑ 155.14% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -47.7M | ↑ 95.69% |
Investing Cash Flow | -303.8M | ↓ 291.73% |
Financing Cash Flow | -743.0K | ↑ 19.84% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -11.8M | ↓ 75.31% |
Investing Cash Flow | 4.8M | ↓ 101.6% |
Financing Cash Flow | -39.0K | ↓ 94.75% |
Sell
Neutral
Buy
Cronos Group Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cronos Group Inc | 4.31% | 23.47% | 33.7% | -66.8% | -83.76% |
![]() Neurocrine Biosciences Inc. | 7.56% | 2.78% | 45.55% | 52.55% | 67.01% |
![]() Haleon Plc Spon Ads | 7.53% | 11.87% | 3.28% | 23.35% | 23.35% |
![]() Zoetis Inc. | 5.77% | -5.62% | -5.85% | -9.99% | 57.03% |
![]() Viatris Inc. | 12.75% | -1.42% | 12.21% | -15.03% | -28.03% |
![]() Catalent, Inc. | 4.08% | 11.91% | 19.53% | -48.27% | 2.08% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cronos Group Inc | NA | NA | NA | -0.08 | -0.05 | -0.04 | NA | 2.82 |
![]() Neurocrine Biosciences Inc. | 39.75 | 39.75 | 0.44 | 3.99 | 0.18 | 0.1 | NA | 23.72 |
![]() Haleon Plc Spon Ads | 29.9 | 29.9 | 1.69 | 0.39 | 0.07 | 0.04 | 0.02 | 1.8 |
![]() Zoetis Inc. | 34.62 | 34.62 | 2.58 | 5.77 | 0.5 | 0.14 | 0.01 | 11.07 |
![]() Viatris Inc. | 224.4 | NA | 0.06 | 2.73 | 0.0 | 0.03 | 0.04 | 16.81 |
![]() Catalent, Inc. | 211.02 | NA | 2.06 | 0.2 | -0.28 | -0.01 | NA | 19.96 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cronos Group Inc | Buy | $911.6M | -83.76% | NA | -61.31% |
![]() Neurocrine Biosciences Inc. | Buy | $14.7B | 67.01% | 39.75 | 18.65% |
![]() Haleon Plc Spon Ads | Buy | $41.0B | 23.35% | 29.9 | 9.64% |
![]() Zoetis Inc. | Buy | $82.0B | 57.03% | 34.62 | 27.38% |
![]() Viatris Inc. | Hold | $14.2B | -28.03% | 224.4 | -0.37% |
![]() Catalent, Inc. | Hold | $10.6B | 2.08% | 211.02 | -28.44% |
Insights on Cronos Group Inc
Revenue is up for the last 2 quarters, 24.57M → 25.17M (in $), with an average increase of 2.4% per quarter
Netprofit is up for the last 2 quarters, -46.04M → -2.23M (in $), with an average increase of 1963.8% per quarter
In the last 1 year, Neurocrine Biosciences Inc. has given 45.5% return, outperforming this stock by 11.8%
In the last 3 years, Neurocrine Biosciences Inc. has given 52.6% return, outperforming this stock by 119.4%
Chescapmanager LLC
Vanguard Group Inc
Tidal Investments LLC.
Point72 Asset Management, L.P.
Dimensional Fund Advisors, Inc.
Two Sigma Investments LLC
cronos group is a globally diversified and vertically integrated cannabis company with a presence across four continents. the company operates two wholly-owned canadian licensed producers regulated under health canada’s access to cannabis for medical purposes regulations: peace naturals project inc. (ontario), which was the first non-incumbent medical cannabis license granted by health canada, and original bc ltd. (british columbia), which is based in the okanagan valley. the company has multiple international production and distribution platforms: cronos israel and cronos australia. through an exclusive distribution agreement, cronos also has access to over 12,000 pharmacies in germany as the company focuses on building an international iconic brand portfolio and developing disruptive intellectual property.
Organization | Cronos Group Inc |
Employees | 356 |
CEO | Mr. Michael Ryan Gorenstein J.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$2.42
+0.0%
Keyarch Acquisition Corp
$2.42
+0.0%
Connexa Sports Technologies Inc
$2.42
+0.0%
Us Value Etf
$2.42
+0.0%
First Wave Biopharma Inc
$2.42
+0.0%
Global X Msci Next Emerging
$2.42
+0.0%
Fat Projects Acquisition Corp
$2.42
+0.0%
Capital Link Global Fintech
$2.42
+0.0%
Applied Uv Inc
$2.42
+0.0%